TW202435855A - 包含阿茲夫定的抗腫瘤藥物組合物 - Google Patents

包含阿茲夫定的抗腫瘤藥物組合物 Download PDF

Info

Publication number
TW202435855A
TW202435855A TW113107353A TW113107353A TW202435855A TW 202435855 A TW202435855 A TW 202435855A TW 113107353 A TW113107353 A TW 113107353A TW 113107353 A TW113107353 A TW 113107353A TW 202435855 A TW202435855 A TW 202435855A
Authority
TW
Taiwan
Prior art keywords
tumor
cancer
egfr
azvudine
pharmaceutical composition
Prior art date
Application number
TW113107353A
Other languages
English (en)
Chinese (zh)
Inventor
磐 李
賈麗敏
秦志勇
王朝陽
Original Assignee
大陸商河南真實生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商河南真實生物科技有限公司 filed Critical 大陸商河南真實生物科技有限公司
Publication of TW202435855A publication Critical patent/TW202435855A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW113107353A 2023-03-03 2024-03-01 包含阿茲夫定的抗腫瘤藥物組合物 TW202435855A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310201580X 2023-03-03
CN202310201580.XA CN116212030A (zh) 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物

Publications (1)

Publication Number Publication Date
TW202435855A true TW202435855A (zh) 2024-09-16

Family

ID=86468723

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113107353A TW202435855A (zh) 2023-03-03 2024-03-01 包含阿茲夫定的抗腫瘤藥物組合物

Country Status (7)

Country Link
US (1) US11878028B1 (https=)
EP (1) EP4424310B1 (https=)
JP (1) JP7783217B2 (https=)
KR (1) KR20250166964A (https=)
CN (1) CN116212030A (https=)
TW (1) TW202435855A (https=)
WO (1) WO2024183644A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物
CN116196325A (zh) * 2023-03-10 2023-06-02 河南真实生物科技有限公司 包含阿兹夫定的免疫调节剂组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
CN102000103B (zh) * 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
CN113171350B (zh) * 2015-06-03 2023-05-26 南京三迭纪医药科技有限公司 药品剂型及其使用
CN109562176A (zh) * 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
TWI818007B (zh) * 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI762784B (zh) * 2018-05-23 2022-05-01 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
EP3954682A4 (en) * 2019-04-09 2022-10-12 Henan Genuine Biotech Co., Ltd. 2-(2,4,5-substituted phenylamino)pyrimidine derivative and crystal form b thereof
CN110003183A (zh) * 2019-04-09 2019-07-12 河南真实生物科技有限公司 2-（2，4，5-取代苯氨基）嘧啶衍生物及其晶形b
JP2023510426A (ja) * 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
CN114191558A (zh) * 2020-09-17 2022-03-18 上海翰森生物医药科技有限公司 Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
CN114569728B (zh) * 2020-11-30 2023-11-28 诺未科技（北京）有限公司 一种组合物及其应用和药物
CN115006397A (zh) * 2021-03-05 2022-09-06 上海翰森生物医药科技有限公司 一种预防或治疗肿瘤疾病的药物用途
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Also Published As

Publication number Publication date
JP7783217B2 (ja) 2025-12-09
CN116212030A (zh) 2023-06-06
EP4424310A1 (en) 2024-09-04
JP2024125139A (ja) 2024-09-13
WO2024183644A1 (zh) 2024-09-12
KR20250166964A (ko) 2025-11-28
EP4424310C0 (en) 2025-07-16
US11878028B1 (en) 2024-01-23
EP4424310B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
TW202435855A (zh) 包含阿茲夫定的抗腫瘤藥物組合物
CN113301895B (zh) 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN119733053A (zh) Kras g12c抑制剂与米托蒽醌的药物组合及其用途
TWI754170B (zh) Ｊａｋ激酶抑制劑與ｅｇｆｒ抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
TW202435896A (zh) 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物
CN111184863A (zh) 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
CN103476413B (zh) 组合
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
US12048711B2 (en) Composition and use thereof in the manufacture of medicament for treating cancer
US20210220362A1 (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
CN115243719B (zh) CTB006与Ponatinib联合应用
WO2023169488A1 (zh) 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
CN114569619A (zh) Pi3k抑制剂单用或联合egfr抑制剂在制备治疗头颈癌或胃癌的药物中的用途
US12336996B2 (en) Drug combination containing TLR7 agonist
WO2025070603A1 (ja) 血液がんの新規併用療法
KR20250088371A (ko) Ezh2 저해제 및 jak3 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
HK40059772A (en) Composition and application thereof in preparation of medicament for treating cancer
HK40059774A (en) Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer
CN117482236A (zh) 小分子酪氨酸激酶抑制剂和stat3抑制剂在制备治疗头颈鳞状细胞癌药物中的应用
CN119326894A (zh) Gsdme抑制剂用于制造预防和治疗化疗时外周神经损伤的药物的用途